CIK 0001593899 · Non-accelerated filer<br>Smaller reporting company
Atea Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AVIR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 460574869
- Phone
- (857) 284-8891
- Business address
- 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-31 | Hammond Janet MJ Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2021-12-20 | Murphy Polly A. Director | Purchase | +12,000 | $8.57 | $103K | 23,295 |
| 2021-06-18 | Polsky Bruce Director | Grant or award · Stock Option (Right to Buy) | +34,025 | 34,025 | ||
| 2021-06-18 | Lucidi Bruno Director | Grant or award · Stock Option (Right to Buy) | +34,025 | 34,025 | ||
| 2021-06-18 | Duncan Barbara Gayle Director | Grant or award · Stock Option (Right to Buy) | +34,025 | 34,025 | ||
| 2021-06-18 | BERGER FRANKLIN M Director | Grant or award · Stock Option (Right to Buy) | +34,025 | 34,025 | ||
| 2021-06-18 | Murphy Polly A. Director | Grant or award · Stock Option (Right to Buy) | +34,025 | 34,025 | ||
| 2021-05-18 | Adams Jerome M. Director | Grant or award · Stock Option (Right to Buy) | +56,670 | 56,670 | ||
| 2021-01-29 | Sommadossi Jean-Pierre President, CEO, and Chairman | Grant or award · Stock Option (Right to Buy) | +640,000 | 640,000 | ||
| 2021-01-29 | Hammond Janet MJ Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +160,050 | 160,050 | ||
| 2021-01-29 | Corcoran Andrea See Remarks | Grant or award · Stock Option (Right to Buy) | +148,850 | 148,850 | ||
| 2021-01-29 | Vavricka John Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +117,300 | 117,300 | ||
| 2021-01-29 | Horga Maria Arantxa Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +145,500 | 145,500 | ||
| 2021-01-29 | Foster Wayne See Remarks | Grant or award · Stock Option (Right to Buy) | +71,750 | 71,750 | ||
| 2020-11-03 | Cormorant Asset Management, LP Former 10% Owner | Conversion | +6,411,355 | 6,411,355 | ||
| 2020-11-03 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series A Convertible Preferred Stock | −1,000,000 | 0 | ||
| 2020-11-03 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series B Convertible Preferred Stock | −1,650,165 | 0 | ||
| 2020-11-03 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series C Convertible Preferred Stock | −2,631,580 | 0 | ||
| 2020-11-03 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series D Convertible Preferred Stock | −712,250 | 0 | ||
| 2020-11-03 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series D-1 Convertible Preferred Stock | −417,360 | 0 |
Page 12 of 14 · 280 trades